• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

癌症临床研究的资格：发现、可推广性、惠益和公正的交集。

Eligibility in Cancer Clinical Research: The Intersection of Discovery, Generalizability, Beneficence, and Justice.

机构信息

Division of Hematology and Oncology, Massachusetts General Hospital, Boston, Massachusetts.

出版信息

Clin Cancer Res. 2021 May 1;27(9):2369-2371. doi: 10.1158/1078-0432.CCR-21-0085. Epub 2021 Feb 18.

DOI:10.1158/1078-0432.CCR-21-0085
PMID:33602680
Abstract

Eligibility criteria in clinical trials limit the study population for safety and scientific purposes. The American Society of Clinical Oncology and The Friends of Cancer Research collaboration reconsidered common eligibility criteria in cancer trials and found many to be unnecessarily restrictive. The current recommendations further their efforts to facilitate accrual and improve the generalizability of research results to practice..

摘要

临床试验的入选标准出于安全性和科学性的目的对研究人群加以限制。美国临床肿瘤学会与癌症研究之友合作组织重新审议了癌症试验中的常见入选标准，并发现许多标准过于严格。目前的建议进一步促进了研究人群的纳入，并提高了研究结果在实践中的普遍性。

相似文献

1
Eligibility in Cancer Clinical Research: The Intersection of Discovery, Generalizability, Beneficence, and Justice.癌症临床研究的资格：发现、可推广性、惠益和公正的交集。
Clin Cancer Res. 2021 May 1;27(9):2369-2371. doi: 10.1158/1078-0432.CCR-21-0085. Epub 2021 Feb 18.
2
Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement.扩大入选标准以使临床试验更具代表性：美国临床肿瘤学会与癌症研究之友联合研究声明
J Clin Oncol. 2017 Nov 20;35(33):3737-3744. doi: 10.1200/JCO.2017.73.7916. Epub 2017 Oct 2.
3
Examining Exclusion Criteria in Advanced Prostate Cancer Clinical Trials: An Assessment of recommendations From the American Society Of Clinical Oncology and Friends of Cancer Research.审查晚期前列腺癌临床试验的排除标准：对美国临床肿瘤学会和癌症研究之友的建议的评估。
Clin Genitourin Cancer. 2023 Dec;21(6):e467-e473. doi: 10.1016/j.clgc.2023.05.013. Epub 2023 May 24.
4
Reappraisal of eligibility criteria in cancer clinical trials.癌症临床试验入选标准的再评价。
Curr Opin Oncol. 2018 Sep;30(5):352-357. doi: 10.1097/CCO.0000000000000470.
5
Removing barriers to participation in clinical trials, a conceptual framework and retrospective chart review study.消除参与临床试验的障碍：概念框架与回顾性图表审查研究。
Trials. 2012 Dec 10;13:237. doi: 10.1186/1745-6215-13-237.
6
Continuing to Broaden Eligibility Criteria to Make Clinical Trials More Representative and Inclusive: ASCO-Friends of Cancer Research Joint Research Statement.持续拓宽资格标准以使临床试验更具代表性和包容性：美国临床肿瘤学会 - 癌症研究之友联合研究声明
Clin Cancer Res. 2021 May 1;27(9):2394-2399. doi: 10.1158/1078-0432.CCR-20-3852. Epub 2021 Feb 9.
7
Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Performance Status Work Group.临床研究纳入标准的现代化：ASCO-癌症研究之友绩效状态工作组的建议。
Clin Cancer Res. 2021 May 1;27(9):2424-2429. doi: 10.1158/1078-0432.CCR-20-3868. Epub 2021 Feb 9.
8
False data & the therapeutic misconception: two urgent problems in research ethics. False data and last hopes: enrolling ineligible patients in clinical trials.
Hastings Cent Rep. 1987 Apr;17(2):16-9.
9
Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Brain Metastases Working Group.临床研究纳入标准的现代化：美国临床肿瘤学会-癌症研究之友脑转移工作组的建议。
J Clin Oncol. 2017 Nov 20;35(33):3760-3773. doi: 10.1200/JCO.2017.74.0761. Epub 2017 Oct 2.
10
Cancer clinical trials in the USA: patient eligibility, generalizability of results and technology transfer.美国的癌症临床试验：患者资格、结果的可推广性及技术转让
Bull Cancer. 1987;74(2):197-203.

引用本文的文献

1
Reflections and insights into the evolution of restrictive eligibility criteria for cancer clinical trials in China and beyond.对中国及其他地区癌症临床试验限制性入选标准演变的思考与见解。
Cancer Commun (Lond). 2025 Jun;45(6):673-676. doi: 10.1002/cac2.70007. Epub 2025 Mar 12.
2
Optimizing early phase clinical trial washout periods: a report from the Therapeutic Advances in Childhood Leukemia and Lymphoma consortium.优化早期临床试验洗脱期：来自儿童白血病和淋巴瘤治疗进展联盟的报告。
J Natl Cancer Inst. 2024 Nov 1;116(11):1721-1729. doi: 10.1093/jnci/djae165.
3
Quantitative evaluation of the impact of relaxing eligibility criteria on the risk-benefit profile of drugs for lung cancer based on real-world data.
基于真实世界数据定量评估放宽肺癌药物资格标准对其风险效益比的影响。
Thorac Cancer. 2024 May;15(14):1187-1194. doi: 10.1111/1759-7714.15269. Epub 2024 Apr 4.
4
Addressing disparities in cancer clinical trials: a roadmap to more equitable accrual.解决癌症临床试验中的差异：实现更公平入组的路线图。
Front Health Serv. 2024 Mar 8;4:1254294. doi: 10.3389/frhs.2024.1254294. eCollection 2024.